Results 31 to 40 of about 59,740 (225)

The Alzheimer variant of Lewy body disease: A pathologically confirmed case-control study [PDF]

, 2005
The objective of the study was to identify clinical features that distinguish patients with dementia with Lewy bodies (DLB), who were classified as Alzheimer's disease ( AD) patients, from patients with AD.
Busch, R., Förstl, Hans, Kretzschmar, H., Kurz, A., Mösch, D., Müller, U., Neumann, M., Perneczky, R.   +7 more
core   +1 more source

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. [PDF]

, 2015
OBJECTIVE: The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia.
Cambridge, Victoria, Lafortune, Louise, Mak, Elijah, Mason, James, McKeith, Ian, Mioshi, Eneida, O'Brien, John T, Stinton, Chris, Taylor, John-Paul, Thomas, Alan   +9 more
core   +2 more sources

Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience [PDF]

, 2008
Background: Dementia results from heterogeneous diseases of the brain. Mixed disease forms are increasingly recognized. Methods: We performed a survey within brain banks of BrainNet Europe to estimate the proportion of mixed disease forms underlying ...
Al-Sarraj, Safa, Alafuzoff, Irina, Arzberger, Thomas, Bogdanovic, Nenad, Budka, Herbert, Capellari, Sabina, Ferrer, Isidro, Gelpi, Ellen, Kovacs, Gabor G., Kovari, Viktor, Kretzschmar, Hans, Nagy, Zoltan, Parchi, Piero, Seilhean, Danielle, Soininen, Hilkka, Troakes, Claire   +15 more
core   +1 more source

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. [PDF]

, 2019
The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid into plaques and hyperphosphorylated tau into tangles.
Brundin, P, Cambi, F, Espay, AJ, Fasano, A, Fernandez, HH, Gan-Or, Z, Greenamyre, JT, Josephs, KA, Kauffman, MA, Lang, AE, Leverenz, JB, Litvan, I, Marsili, L, Mata, IF, Merola, A, Morgante, F, Perry, G, Sardi, SP, Savica, R, Schwarzschild, MA, Sherer, T, Simon, DK, Standaert, DG, Tanner, CM, Vizcarra, JA, Yamasaki, TR, Zabetian, CP   +26 more
core   +3 more sources

Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.

PLoS ONE, 2013
ObjectiveMost neurodegenerative diseases contain hyperphosphorylated Tau [p-Tau]. We examined for the first time epitopes at which Tau is hyperphosphorylated in Parkinson's disease, dementia with Lewy bodies and Alzheimer's disease, and also select Tau ...
Valeriy Duka, Jae-Hoon Lee, Joel Credle, Jonathan Wills, Adam Oaks, Ciaran Smolinsky, Ketul Shah, Deborah C Mash, Eliezer Masliah, Anita Sidhu   +9 more
doaj   +1 more source

Introduction of an assessment toolkit associated with increased rate of DLB diagnosis

Alzheimer’s Research & Therapy, 2021
Background Dementia with Lewy bodies (DLB) and dementia in Parkinson’s disease (PDD) are recognised to be under-recognised in clinical practice in the UK, with only one third to a half of expected cases diagnosed.
A. Surendranathan, J. Kane, A. Bentley, S. Barker, R. McNally, C. Bamford, J.-P. Taylor, A. Thomas, I. McKeith, D. Burn, J. T. O’Brien   +10 more
doaj   +1 more source

An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy [PDF]

, 2015
BackgroundImaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission ...
Cam Donaldson, Christopher Davison, David Williams, Fahn, Jim Lloyd, John T. O'Brien, Karl Herholz, Kirsty Olsen, Michael J. Firbank, Nicky Barnett, Robert Barber, Roth, Schmidt, Sean J. Colloby   +13 more
core   +1 more source

Parkinson's disease dementia: a neural networks perspective. [PDF]

, 2015
In the long-term, with progression of the illness, Parkinson's disease dementia affects up to 90% of patients with Parkinson's disease. With increasing life expectancy in western countries, Parkinson's disease dementia is set to become even more ...
Foltynie, T, Gratwicke, J, Jahanshahi, M
core   +1 more source

Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. [PDF]

, 2014
BackgroundIn dementia with Lewy bodies (DLB) abnormal interactions between α-synuclein (α-syn) and beta amyloid (Aβ) result in selective degeneration of neurons in the neocortex, limbic system and striatum.
Cartier, Anna, Desplats, Paula, Masliah, Eliezer, Overk, Cassia R, Patrick, Christina, Price, Diana L, Rockenstein, Edward, Shaked, Gideon, Spencer, Brian, Ubhi, Kiren   +9 more
core   +3 more sources

Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
Dementia with Lewy bodies (DLB) research has seen a significant growth in international collaboration over the last three decades. However, researchers face a challenge in identifying large and diverse samples capable of powering longitudinal studies and
Fabrizia D'Antonio, Joseph P.M. Kane, Agustin Ibañez, Simon J.G. Lewis, Richard Camicioli, Huali Wang, Yueyi Yu, Jing Zhang, Yong Ji, Miguel Germán Borda, Rukmini Mridula Kandadai, Claudio Babiloni, Laura Bonanni, Manabu Ikeda, Bradley F. Boeve, James B. Leverenz, Dag Aarsland, the ISTAART Lewy body dementias Consortia Working Group   +17 more
doaj   +1 more source